Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 576-585

  Diamantopoulos, Alexander ^a   Benucci, Maurizio ^b   Capri, Stefano ^c   Berger, Wolfgang ^d   Wintfeld, Neil ^e   Giuliani, Giovanni ^d   Ricciardi, Walter ^f  

^a Showa University Koto Hospital   (United Kingdom)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^c CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e GENENTECH INC   (United States)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cost effectiveness; Cost utility analysis; Disease severity; Disease modifying anti rheumatic drugs; Health related quality of life; Pharmacoeconomic modeling; Resource utilization; Rheumatoid arthritis; Standard of care; Tocilizumab (additional) biologics; Treatment related costs

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; ITALY; MALE; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; ITALY; MALE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859205842     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.665110     Document Type: Article

References (35)

1. Salaffi F, De Angelis R, Grassi W. MArche Pain Prevalence INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: Results of a regional community-based study, I: The MAPPING study. Clin Exp Rheumatol 2005;23:819-28
2. Leardini G, Salaffi F, Montanelli R, et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20:505-15
3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69: 964-975
4. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomized trial. Lancet 2008;371:987-97
5. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
6. Fleischmann R, Burgos-Vargas R, Ambs P, et al. LITHE: Tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients (Pts) at 2 yrs with increasing clinical efficacy over time [abstract]. Arthritis Rheum 2009;60(10 Suppl):637
7. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance (130): Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Issued October 2007. http://www.nice.org.uk/ nicemedia/pdf/TA130guidance.pdf. Accessed March 30, 2011
8. Benucci M, Li Gobbi F, Sabadini L, et al. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: Cost-effectiveness analysis of sub-cutaneous anti-TNFa treatment in Italian patients. Int J Immunopathol Pharmacol 2009;22:1147-52
9. De Portu S, Mantovani LG, Olivieri I. Analisi di costo-utilità di abatacept nell'artrite reumatoide in Italia. Farmeconomia e Percorsi Terapeutici 2008;9:19-26
10. Leardini G, Ganguly R, Singh A. Cost-effectiveness analysis of etanercept versus infliximab and anakinra in the treatment of rheumatoid arthritis in Italy [abstract 1152]. 67th Annual Scientific Meeting of the American College of Rheumatology (ACR), 23-28 October 2003, Orlando, FL
11. Gabriel S, Drummond M, Maetzel A, et al. Patient Perspective Group. OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90
12. Maetzel A, Tugwell P, Boers M, et al. OMERACT 6 Economics Research Group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a consensus-based reference case. J Rheumatol 2003;30:891-6
13. Kielhorn A, Porter D, Diamantopoulos A, et al. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin 2008;24:2639-50
14. Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: A cost-effectiveness analysis. Arthritis Rheum 2008;58:939-46
15. Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-(alpha) antagonists. J Rheumatol 2008;35:1745-53
16. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-(alpha) antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology (UK) 2007;46:1345-54
17. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006; 24:1221-32
18. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness [abstract]. Health Technol Assess 2006;10:248
19. Jobanputra P, Barton P, Bryan S, et al. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation. Health Technol Assess 2002;6:1-110
20. Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: The case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:1-91
21. Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425-41
22. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006;15:1295-310
23. Davies R, Roderick P, Raftery J. The evaluation of disease prevention and treatment using simulation models. Eur J Operational Res 2003;150:53-66
24. van Vollenhoven R, Ducournau P, Wintfeld N, et al. Health Assessment Questionnaire-Disability Index scores in patients with rheumatoid arthritis treated with tocilizumab plus conventional anti-rheumatic drugs. Presented at: ISPOR 12th Annual European Congress, 24-27 October 2009, Paris, France
25. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-Term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56
26. Weinblatt ME, Keystone EC, Furst DE, et al. Change over time in the safety, efficacy, and remission profiles of patients with rheumatoid arthritis receiving adalimumab for up to 7 years. Presented at: American College of Rheumatology 2007 Annual Scientific Meeting, 10-11 November 2007, Boston, MA
27. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8
28. Bansback N, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002
29. Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72
30. Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (HUMIRA) [abstract UT3]. Presented at: 7th International Society of Pharmacoeconomics and Outcomes Research, 19-22 May 2002, Arlington, VA
31. Favalli EG, Marchesoni A, Colombo GL, et al. Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 2008;26:45-51
32. Rubio-Terré s C, Ordovà s Baines JP, Pla Poblador R, et al. Grupo de Investigadores del Estudio PRAXIS. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)] [Spanish]. Farm Hosp 2007;31:71-92
33. Benucci M, Iannazzo S, Zaniolo O, et al. Rituximab in the treatment of rheumatoid arthritis patients in Italy: A budget impact analysis. Clin Exp Rheumatol 2010;28:722-7
34. ISTAT Italian Institute of Statistics 2009. Coefficienti per tradurre valori monetari dei periodi sottoindicati in valori del 2010 (a). http://www.istat.it/prezzi/precon/rivalutazioni/val-moneta-2010.zip. Accessed February 7, 2011
35. Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and effect of biologic therapy: A longitudinal observation study. Arthritis Res Ther 2010;12:R35